10-Q: Neuronetics Q1 2026 Results Show Revenue Growth Amidst Going Concern Doubts

Neuronetics reports an 8% increase in Q1 2026 revenue to $34.5 million, driven by clinic services, but faces substantial doubt about its ability to continue as a going concern due to projected covenant breaches.

Summary

• Total revenue for the first quarter of 2026 increased by 8% to $34.5 million, up from $32.0 million in the same period of 2025.
• This revenue growth was primarily driven by a 15% increase in U.S. clinic revenue, reaching $21.5 million, and a 13% increase in U.S. System revenue to $3.2 million.
• However, U.S. treatment session revenue saw a slight decrease of $0.5 million to $9.1 million.
• The company reported a net loss of $10.8 million for the quarter, an improvement from the $12.7 million net loss in Q1 2025.
• Despite revenue growth, the company faces substantial doubt about its ability to continue as a going concern due to projected non-compliance with a minimum revenue covenant in its credit facility by March 31, 2027.
• Cash and cash equivalents decreased to $13.2 million as of March 31, 2026, from $28.1 million as of December 31, 2025.
• Sales and marketing expenses decreased by 11% to $10.7 million, while general and administrative and research and development expenses also saw slight decreases.
• A loss on extinguishment of debt of $0.5 million was recorded in the quarter due to a principal payment and associated fees on the Perceptive Facility.
• The company received $2.2 million in Employee Retention Credit (ERC) proceeds in Q1 2026, with $1.1 million paid to Madryn Asset Management.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant going concern doubts, declining cash reserves, and continued net losses, despite some revenue growth.

Positives

• Total revenue increased by 8% to $34.5 million in Q1 2026 compared to Q1 2025.
• U.S. clinic revenue grew by 15% to $21.5 million.
• U.S. System revenue increased by 13% to $3.2 million.
• Net loss improved to $10.8 million from $12.7 million in the prior year's quarter.
• Sales and marketing expenses decreased by 11%.
• The company was in compliance with its credit facility covenants as of March 31, 2026, following amendments made in March 2026.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to projected non-compliance with a minimum revenue covenant in its credit facility by March 31, 2027.
• Cash and cash equivalents decreased significantly to $13.2 million from $28.1 million.
• Gross margin decreased from 49.2% to 46.9% due to changes in revenue mix.
• U.S. treatment session revenue declined by $0.5 million.
• Interest expense increased by 18% to $2.3 million due to a higher outstanding debt balance.
• A $0.5 million loss on extinguishment of debt was incurred.
• The company is subject to ongoing investigations related to federal healthcare program billing practices.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to projected failure to meet minimum revenue covenants under its credit facility.
• If the lender calls the credit facility due to covenant breach, the company may not have sufficient liquidity to repay the loan.
• The company's recurring losses and negative cash flow raise concerns about future profitability and liquidity.
• Failure to secure adequate future financing could adversely affect the business, financial condition, and results of operations.
• The company is subject to ongoing investigations by the U.S. Attorneys Office and state attorneys general regarding federal healthcare program billing practices, which could result in significant penalties.
• Geopolitical instability, inflation, and supply chain disruptions could adversely affect global economic conditions and the company's business.
• The company relies on the sale and usage of its NeuroStar System, and any issues with demand, reimbursement, or competition could impact revenue.
• The company's ability to meet future liquidity needs is dependent on growth in its product and service lines and realization of synergies from the Greenbrook acquisition.

Future Outlook

The company anticipates operating losses will continue in the near term due to ongoing investments in sales and marketing and product development. Management projects trailing twelve-month revenue for the period ended March 31, 2027 to be below the minimum required revenue for that period as stated in the credit facility agreement, raising concerns about the company's ability to continue as a going concern. Additional actions to meet covenants include improvements to revenue cycle management, introducing new treatment options, and pursuing new strategies in the medical device business.

Management Comments

• "We incurred negative cash flows from operating activities of $9.4 million for the three months ended March 31, 2026 and $20.4 million for the year ended December 31, 2025."
• "The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales and marketing and product development activities."
• "The Company currently projects trailing twelve-month revenue for the period ended March 31, 2027 to be below the minimum required revenue for that period as stated in the credit facility agreement."
• "Should the Company not be able to meet its March 31, 2027 minimum revenue covenant, the lender may at that time and at its discretion, call the credit facility. Should the lender call the facility, the Company is not projected to have the liquidity required to meet its requirement to pay off the loan."
• "Therefore, substantial doubt exists about the Companys ability to continue as a going concern."
• "Additional actions within the Company's control to meet its minimum revenue covenant include improvements to its revenue cycle management, introducing new treatment options at its clinic locations and pursuing new strategies within its medical device business to accelerate sales growth and optimize its product mix."
• "We anticipate that our sales and marketing expenses will decrease in 2026 relative to 2025 as a result of the cost efficiencies realized post-acquisition across the sales and marketing divisions."
• "We anticipate that our general and administrative expenses will increase in 2026 from 2025 due to an increase in the overall size of the general and administrative function within the consolidated company and investments needed to streamline systems and leverage automation."
• "We expect our research and development expenses to remain consistent during 2026 compared to 2025 expenses."

Industry Context

StockSavvy.ai notes that Neuronetics' Q1 2026 results reflect the ongoing challenges faced by medical device companies in balancing revenue growth with significant operating expenses and debt obligations. The company's reliance on clinic revenue, which grew robustly, highlights the integration success of the Greenbrook acquisition, but the persistent net losses and going concern doubts underscore the capital-intensive nature of this sector and the critical importance of managing debt covenants.

Comparison to Industry Standards

• Neuronetics' gross margin of 46.9% is lower than some established medical device companies, which often achieve gross margins in the 60-70% range, suggesting potential areas for cost optimization or pricing power improvements.
• The company's net loss of $10.8 million on $34.5 million in revenue is a common characteristic of early-stage or growth-phase medical technology companies investing heavily in sales, marketing, and R&D. However, the duration of these losses and the proximity to covenant breaches are critical differentiators.
• The significant decrease in sales and marketing expenses (11%) while revenue grew suggests improved efficiency or a strategic shift in spending, which is positive if sustainable, but could also indicate reduced market penetration efforts.
• The substantial doubt about the company's ability to continue as a going concern is a critical red flag, even for companies in the healthcare sector that often require significant upfront investment. This situation is more severe than typical industry benchmarks for companies at a similar revenue stage.

Management Changes

Legal Proceedings

• A subsidiary received a Civil Investigative Demand (CID) from the U.S. Attorneys Office for the Middle District of Florida regarding federal healthcare program billing practices for periods prior to the Greenbrook acquisition.
• The Michigan Attorney General's office opened a similar investigation.
• The company is cooperating with these investigations and expects similar inquiries from other districts and states.
• The company is subject to various claims and legal actions arising in the ordinary course of business, but management believes none are expected to have a material adverse effect.

Related Party Transactions

• The company paid $1.1 million of Employee Retention Credit (ERC) proceeds to Madryn Asset Management, LP, its largest stockholder, as part of an agreement related to a Term Loan and Exchange Agreement with Greenbrook prior to the acquisition. Avinash Amin, M.D., a representative of Madryn, serves on the Board.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, continued uncertainty regarding profitability and going concern status.
• Creditors: Increased risk due to projected covenant breaches and potential call of the credit facility.
• Employees: Uncertainty related to the company's going concern status could impact job security and morale.
• Customers/Physicians: Continued availability of Neuronetics' products and services is dependent on the company's financial stability.
• Government Agencies (Payors): Ongoing investigations into billing practices could lead to penalties and reputational damage.

Next Steps

• The company is actively engaged in discussions with its lender regarding the credit facility covenants.
• Neuronetics plans to implement improvements in revenue cycle management, introduce new treatment options, and pursue new strategies in its medical device business to accelerate sales growth and optimize its product mix.
• The company will continue to monitor macroeconomic impacts on its business.
• The company will continue to cooperate with ongoing investigations related to federal healthcare program billing practices.

Key Dates

Recommendation

While Neuronetics shows revenue growth and improved net loss, the substantial doubt about its ability to continue as a going concern due to projected credit facility covenant breaches is a significant risk. The company is actively negotiating with its lender and has available ATM capacity, but the path to sustained profitability and financial stability remains uncertain. Investors should hold positions while monitoring the outcome of these negotiations and the company's ability to execute its turnaround plan.

Keywords

Neuronetics, 10-Q, Quarterly Report, Form 10-Q, SEC Filing, NeuroStar, TMS, Major Depressive Disorder, MDD, Obsessive-Compulsive Disorder, OCD, Mental Health, Clinic Revenue, Medical Device, Going Concern, Credit Facility, Financial Statements, Revenue, Net Loss